Research
Hormonal
GLP-1 receptor agonists reduce food intake and body weight in humans, with efficacy comparable to or rivaling bariatric surgery.
GLP-1 medications are effective for weight loss and may eventually rival bariatric surgery in efficacy. They offer a non-surgical option for treating obesity.
StrongSupportsHIGH confidence
Progressive improvements in the efficacy of GLP1RA suggest that GLP-1-based therapies may soon rival bariatric surgery as viable options for the treatment of obesity and its complications.
Why this rating
Based on multiple clinical trials and a comprehensive review.
Source
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker · Molecular Metabolism · 2021
DOI 10.1016/j.molmet.2021.101351
narrative_reviewCited 454×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →